The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
Showing 1-7 of 7 articles
Sirolimus-eluting or everolimus-eluting stents for coronary artery disease: 5-year outcomes of the randomised BIOFLOW-IV trial
Slagboom T,
Toelg R,
Witzenbichler B,
Haude M,
Masotti M,
Ruiz Salmeron R,
Witkowski A,
Uematus M,
Takahashi A,
Waksman R,
Saito S
February 20, 2023 | 10.4244/EIJ-D-22-00526
Pulmonary ridge coverage and device-related thrombosis after left atrial appendage occlusion
Freixa X,
Cepas-Guillén P,
Flores-Umanzor E,
Regueiro A,
Sanchis L,
Fernandez-Valledor A,
Brugaletta S,
Carretero M,
Vidal B,
Masotti M,
Martin-Yuste V,
Roqué M,
Sitges M,
Sabaté M
February 5, 2021 | 10.4244/EIJ-D-20-00886
BIOFLOW-IV, a randomised, intercontinental, multicentre study to assess the safety and effectiveness of the Orsiro sirolimus-eluting stent in the treatment of subjects with de novo coronary artery lesions: primary outcome target vessel failure at 12 months
Saito S,
Toelg R,
Witzenbichler B,
Haude M,
Masotti M,
Ruiz Salmeron R,
Witkowski A,
Uematsu M,
Takahashi A,
Waksman R,
Slagboom T
December 6, 2019 | 10.4244/EIJ-D-18-01214
Randomised comparison of a biodegradable polymer ultra-thin sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients with de novo native coronary artery lesions: the meriT-V trial
Abizaid A,
Kedev S,
Kedhi E,
Talwar S,
Erglis A,
Hlinomaz O,
Masotti M,
Fath-Ordoubadi F,
Lemos P,
Milewski K,
Botelho R,
Costa R,
Bangalore S
December 7, 2018 | 10.4244/EIJ-D-18-00762
Safety and efficacy of a bioabsorbable polymer-coated, everolimus-eluting coronary stent in patients with diabetes: the EVOLVE II diabetes substudy
Kereiakes D,
Meredith I,
Masotti M,
Carrié D,
Moreno R,
Erglis A,
Mehta SR,
Elhadad S,
Berland J,
Stein B,
Airaksinen J,
Jobe R,
Reitman A,
Janssens L,
Christen T,
Dawkins K,
Windecker S
March 20, 2017 | 10.4244/EIJ-D-16-00643
Rationale and design of the RIBS IV randomised clinical trial (drug-eluting balloons versus everolimus-eluting stents for patients with drug-eluting stent restenosis)
Alfonso F,
Pérez-Vizcayno M,
Cardenas A,
García del Blanco B,
García Touchard A,
Lopez-Minguez J,
Rivero F,
Masotti M,
Zueco J,
Cequier A,
Morís C,
Fernandez Ortiz A,
Escaned J,
Jiménez-Quevedo P,
Gonzalo N,
Fernandez C,
Macaya C
July 20, 2015 | 10.4244/EIJY14M09_07
Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent
Meredith I,
Verheye S,
Weissman N,
Barragan P,
Scott D,
Valdés Chávarri M,
West N,
Kelbæk H,
Whitbourn R,
Walters D,
Kubica J,
Thuesen L,
Masotti M,
Banning AP,
Sjogren I,
Stables R,
Allocco DJ,
Dawkins K
July 26, 2013 | 10.4244/EIJV9I3A52
Latest news
AHEAD OF PRINT
Robotic-assisted CABG: clinical outcomes
FREE ARTICLE - Aleksander Dokollari et al
November 23, 2023
PCR London Valves 2023
November 16, 2023
NEW ISSUE
PCR London Valves special edition. State-of-the-art on TMVI; the timing of TMVI; direct wire pacing for TMVR; predicting patient-prosthesis mismatch following TAVI and more
November 17, 2023
AHEAD OF PRINT
Pathophysiological CAD patterns predict outcomes post-PCI
FREE ARTICLE - Nozomi Kotoku et al
November 14, 2023
AHEAD OF PRINT
Cardiac damage classification in each AS subtype
FREE ARTICLE - Masaaki Nakase et al
November 6, 2023
AHEAD OF PRINT
Extra-mitral valve cardiac involvement in MR
FREE ARTICLE - Antonio Popolo Rubbio et al
November 9, 2023
AHEAD OF PRINT
CAPTIS embolic protection during TAVR
FREE ARTICLE - Haim D. Danenberg et al
November 2, 2023